Request A Call Back
Product Description
INDICATION:
Tucatinib is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastaticHER2-positive breast cancer including patients with brain metastases who have received one or more prior anti-HER2-based regimens in the metastatic setting.
DOSAGE AND ADMINISTRATION :
Recommended DosageThe recommended dosage of Tucatinib is 300 mg taken orally twice daily in combinationwith trastuzumab and capecitabine until disease progression or unacceptable toxicity
Patients are advised to swallow Tucatinib tablets whole and not to chew,crush,or split prior to swallowing.Patients are advised not to ingest tablet if it is brokencrackedor not otherwise intact.
Patients are advised to take Tucatinib approximately 12 hours apart and at the same time each daywith or without a meal.
If the patient vomits or misses a dose of TucatinibPatients are advised to take the next dose at its usual scheduled time. When given in combination with Tucatinibthe recommended dosage of capecitabine is 1000mg/m2 orally twice daily taken within 30 minutes after meal.Tucatinib and capecitabine can be taken at the same time.
Dosage Modificationsfor AdverseReactions
Recommended Tucatinib Dose Reductions for Adverse Reactions